Table 1.
Demographics, NP test scores, and APOE genotypes of the studied population
| Characteristics | Healthy control (n = 3514) | Alzheimer's disease (n = 555) | Non-Alzheimer's dementia (n = 443) |
|---|---|---|---|
| Age at NP examination | |||
| Mean (SD) | 79 (6) | 85 (6) | 84 (6) |
| Range | 70–101 | 70–103 | 70–97 |
| Male, no. (%) | 1521 (43.3) | 179 (32.3) | 220 (49.7) |
| Highest level of education attained | |||
| Valid education data, no. (%) | 3510 (99.9) | 549 (98.9) | 442 (99.8) |
| High school and below, no. (%)∗ | 1491 (42.5) | 358 (65.2) | 241 (54.5) |
| Beyond high school, no. (%)∗ | 2019 (57.5) | 191 (34.8) | 201 (45.5) |
| APOE ε4 allele | |||
| Valid genetic data, no. (%)† | 3369 (95.9) | 530 (95.5) | 413 (93.2) |
| APOE ε4 (−), no. (%)∗ | 2794 (82.9) | 346 (65.3) | 327 (79.2) |
| APOE ε4 (+), no. (%)∗ | 575 (17.1) | 184 (34.7) | 86 (20.8) |
| NP test scores, mean (SD) | |||
| LMi | 11.2 (3.7) | 4.8 (3.8) | 7.9 (3.9) |
| LMd | 10.2 (3.9) | 3.0 (4.0) | 6.5 (4.1) |
| LMr | 9.4 (1.4) | 7.1 (2.3) | 8.5 (1.7) |
| VRi | 7.1 (3.0) | 3.1 (2.3) | 4.0 (2.5) |
| VRd | 6.1 (3.1) | 1.6 (1.9) | 2.7 (2.4) |
| VRr | 2.6 (1.1) | 1.3 (1.1) | 1.7 (1.1) |
| PASi | 12.8 (3.3) | 8.4 (2.9) | 9.9 (2.8) |
| PASd_h | 2.0 (1.3) | 0.5 (0.9) | 1.0 (1.1) |
| PASi_h | 4.4 (3.0) | 1.1 (1.7) | 2.0 (2.0) |
| SIM | 15.5 (3.9) | 9.8 (5.0) | 11.6 (4.7) |
| BNT30 | 26.1 (3.4) | 19.4 (5.9) | 22.3 (5.4) |
Abbreviations: APOE, apolipoprotein E; BNT30, Boston Naming Test (30-item Even Version); NP, neuropsychological; LMd, Logical Memory (Delayed Recall); LMi, Logical Memory (Immediate Recall); LMr, Logical Memory (Recognition); PASd_h, Hard score of Paired Associate Learning (Delayed Recall); PASi, Paired Associate Learning (Immediate Recall); PASi_h, Hard Score of Paired Associate Learning (Immediate Recall); SD, standard deviation; SIM, Similarities Test; VRd, Visual Reproductions (Delayed Recall); VRi, Visual Reproductions (Immediate Recall); VRr, Visual Reproductions (Recognition).
Values are calculated based on a subset with valid data.
Participants who did not consent to genetic analyses, had an APOE ε2/ε4 genotype, or with no APOE information were excluded.